CINJ 050707: NO21321: Phase I Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients with Refractory Metastatic or Locally Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2014
At a glance
- Drugs RG 4733 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 19 Sep 2011 Actual end date Jan 2011 added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2010 Planned end date changed from 1 May 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.